Xiao-yu Jia

Key Laboratory Of Chronic Kidney Disease Prevention And Treatment
Beijing, 100034, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease.

Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease.

Journal: International journal of molecular sciences

Published: March 26, 2026

Acetate ameliorates membranous nephropathy by modulating the immune response and podocyte function.

Acetate ameliorates membranous nephropathy by modulating the immune response and podocyte function.

Journal: BMC nephrology

Published: January 16, 2026

Elevated serum soluble α3(IV)NC1 correlates with kidney injury and worse outcome in patients with anti-glomerular basement membrane disease.

Elevated serum soluble α3(IV)NC1 correlates with kidney injury and worse outcome in patients with anti-glomerular basement membrane disease.

Journal: Frontiers in immunology

Published: October 19, 2025

In vivo Expansion of Regulatory T cells via an Engineered IL-2 Mutein to Suppress Autoimmune Glomerulonephritis.

In vivo Expansion of Regulatory T cells via an Engineered IL-2 Mutein to Suppress Autoimmune Glomerulonephritis.

Journal: Theranostics

Published: October 11, 2025

Anti-glomerular basement membrane disease: variant forms and underlying mechanisms.

Anti-glomerular basement membrane disease: variant forms and underlying mechanisms.

Journal: Kidney international

Published: September 12, 2025

The Hippo pathway: potential target for immunotherapy of crescentic glomerulonephritis.

The Hippo pathway: potential target for immunotherapy of crescentic glomerulonephritis.

Journal: Frontiers in immunology

Published: July 24, 2025

Serum matrix metalloproteinase-9 levels and enzymatic activity in patients with anti-glomerular basement membrane disease.

Serum matrix metalloproteinase-9 levels and enzymatic activity in patients with anti-glomerular basement membrane disease.

Journal: Frontiers in medicine

Published: July 18, 2025

Bowman's capsule rupture and its clinical significance in patients with anti-glomerular basement membrane disease.

Bowman's capsule rupture and its clinical significance in patients with anti-glomerular basement membrane disease.

Journal: Frontiers in immunology

Published: June 27, 2025

Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease.

Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: May 08, 2025

Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: A systematic review and meta-analysis.

Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: A systematic review and meta-analysis.

Journal: Autoimmunity reviews

Published: March 04, 2024

Short-chain fatty acids ameliorate experimental anti-glomerular basement membrane disease.

Short-chain fatty acids ameliorate experimental anti-glomerular basement membrane disease.

Journal: Clinical immunology (Orlando, Fla.)

Published: September 09, 2023

Evaluation of the Risk Prediction Models in Predicting Kidney Outcomes in Antiglomerular Basement Membrane Disease.

Evaluation of the Risk Prediction Models in Predicting Kidney Outcomes in Antiglomerular Basement Membrane Disease.

Journal: Kidney international reports

Published: June 03, 2023

Showing 1-12 of 46

Last Updated: 09/26/2026